• Gramine, CUL3–MTDH, and Ferroptosis in TNBC

  2026-09-03

  This 2026 study identifies a CUL3–MTDH regulatory axis through which gramine suppresses triple-negative breast cancer by promoting ferroptosis. Its combination of target-engagement assays, ferroptosis rescue experiments, genetic perturbation, and xenograft validation provides a mechanistic framework for evaluating gramine as an experimental TNBC candidate.

• Chloroquine Research Workflows and Troubleshooting

  2026-09-02

  Build reproducible Chloroquine experiments around lysosomal pH, autophagy flux, inflammatory signaling, and exposure-response design. This guide connects cancer, malaria, viral, and rheumatoid arthritis research while highlighting formulation controls, pharmacogenomic variables, and practical troubleshooting.

• Cefepime (BMY-28142) in Resistance Research

  2026-09-02

  Cefepime (BMY-28142) supports more than routine susceptibility testing: it can connect phenotype, resistance-gene mobility, and blood-brain barrier model data. This workflow-focused guide shows how to build reproducible bacterial infection model assays while controlling solution stability and neurotoxicity-related confounding.

• MK-8745: A Mechanism-First Aurora A Strategy

  2026-09-01

  Explore how MK-8745, a potent and selective Aurora A inhibitor, can distinguish Aurora A expression from functional dependency across mitotic arrest, apoptosis, lymphoma, and xenograft research. This mechanism-first guide translates recent retinoblastoma evidence into better model selection and assay interpretation.

• Leucovorin Calcium in Gastric Assembloid Assays

  2026-09-01

  Leucovorin Calcium, also known as calcium folinate, can help dissect folate-dependent rescue in patient-derived gastric assembloids. This article presents a causal assay framework that separates methotrexate rescue, stromal protection, and genuine antifolate resistance.

• Mycophenolic acid for Reliable Cell Assays

  2026-08-31

  Learn how Mycophenolic acid (SKU B1981) can help researchers distinguish metabolic suppression from true cytotoxicity, standardize solvent handling, and interpret immunometabolic assay results. The article combines product specifications with a peer-reviewed whole-blood stimulation protocol to support more reproducible experimental decisions.

• Palmitic acid: Protocol and QC Guide

  2026-08-30

  Palmitic acid (hexadecanoic acid, SKU N2456) provides a characterized saturated long-chain fatty acid for controlled studies of lipid metabolism, insulin signaling, inflammation, and protein palmitoylation. It is intended for dry storage and non-aqueous preparation, not water-based assays or long-term storage of working solutions.

• Flumequine for DNA Topoisomerase II Assays

  2026-08-29

  Flumequine supports mechanism-focused topoisomerase II experiments as well as time-resolved cancer cell-response profiling. This workflow separates proliferation arrest from cell killing, helping researchers interpret DNA replication and repair phenotypes more accurately.

• Nullscript: HDAC Inhibition in Cardiac I/R

  2026-08-29

  Nullscript is a histone deacetylase inhibitor and close analog of scriptaid with an unusual transcriptional-facilitation profile. Product information reports approximately 46.8% in vivo myocardial infarct size reduction in a murine cardiac ischemia/reperfusion model, while clinical efficacy and human safety remain unestablished.

• LY294002: A Mechanistic Guide to PI3K Assays

  2026-08-28

  LY294002 is a reversible PI3K inhibitor widely used to dissect PI3K/Akt/mTOR signaling. This assay-focused guide explains how to interpret its effects in cancer and pulmonary fibrosis models while accounting for pathway crosstalk, autophagy, and off-target BET activity.

• Losartan: AT1 Blockade for Vascular Research

  2026-08-28

  Losartan is an angiotensin II receptor antagonist that selectively blocks AT1-mediated signaling in cardiovascular physiology and hypertension research. Its reported receptor-binding IC50 is approximately 20 nM, while product data support workflows involving vascular smooth muscle cell proliferation inhibition and blood-pressure studies.

• Diphenyleneiodonium Chloride in Redox Assays

  2026-08-27

  Diphenyleneiodonium chloride, or DPI, is a versatile mechanistic probe for separating oxidase-driven redox changes from receptor-linked cAMP signaling. This workflow shows how to use it in Nrf2, oxidative stress, viral infection, and cell-death assays while controlling for dose, timing, solvent, and off-target effects.

• 3-Deazaadenosine Hydrochloride: Assay Design

  2026-08-27

  Explore how 3-Deazaadenosine hydrochloride can be used to interrogate SAHH-dependent methylation in hepatic stellate cell research. This guide connects biochemical inhibition with m6A assay design, causal controls, and practical workflow decisions.

• Stat3 in Fyn-Driven Dopaminergic Neurodegeneration

  2026-08-26

  A 2024 Disease Models & Mechanisms study developed a neural-specific zebrafish model of constitutively active Fyn kinase and linked Fyn signaling to dopaminergic neuron loss, mitochondrial abnormalities, and microglial inflammation. Live imaging, transcriptomics, and pathway inhibition identified Stat3 as a downstream effector that cooperates with NF-κB, providing a mechanistic framework for studying kinase-driven neurodegeneration.

• Novobiocin: Designing Time-Resolved Antimicrobial Assays

  2026-08-26

  Novobiocin is an aminocoumarin antibiotic whose effects extend beyond simple growth inhibition. This guide shows how to use temporal perturbation, DNA measurements, and morphology to distinguish replication arrest from downstream membrane and vacuole phenotypes.

454 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page